GlassScriptPhysician profile
Susan E Elrod
NPI 1063418713
$9,936.66
in general payments reported to CMS, 2019-2025
28 companies · $2,497 in 2025
The $2,497 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,465 · 2022: $2,133 · 2023: $1,765 · 2024: $2,077 · 2025: $2,497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,105 · Education: $234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,105.32 |
| Education | $233.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,161.46 | 2021-2025 | |
| Abbvie INC. | $1,949.31 | 2021-2025 | |
| Ucb, INC. | $794.96 | 2021-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $762.96 | 2021-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $752.35 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $584.13 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $549.29 | 2021-2025 | Nemluvio, Aklief, Twyneo |
| Janssen Biotech, INC. | $474.09 | 2021-2025 | Tremfya |
| Amgen INC. | $282.69 | 2021-2024 | Otezla |
| Incyte Corporation | $261.48 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $211.75 | 2021-2025 | Winlevi, Absorica Ld |
| Dermavant Sciences, INC. | $156.59 | 2022-2023 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.42 | 2023-2025 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $148.64 | 2021-2025 | Cabtreo, Jublia |
| Pfizer INC. | $143.47 | 2021-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $118.99 | 2025 | Vtama |
| Genzyme Corporation | $99.54 | 2021-2022 | |
| Almirall LLC | $62.40 | 2021-2025 | Seysara |
| Arcutis Biotherapeutics, INC. | $45.46 | 2023 | |
| Kyowa Kirin, INC. | $34.38 | 2024 | Poteligeo |
| Genentech USA, INC. | $34.24 | 2022 | |
| Leo Pharma INC. | $33.71 | 2022-2025 | Anzupgo |
| Epi Health, LLC | $25.91 | 2022 | |
| Journey Medical Corporation | $22.53 | 2023 | |
| Sebela Pharmaceuticals INC. | $20.86 | 2021 | |
| Vyne Pharmaceuticals INC. | $19.02 | 2021 | |
| Botanix Sb INC | $17.69 | 2025 | Sofdra |
| Nabriva Therapeutics, Plc | $15.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Elrod listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.